Navigation Links
Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
Date:1/19/2009

HOLLYWOOD, Fla., Jan. 19 /PRNewswire/ -- Stents can be placed in the brain to treat a stroke as it's occurring, suggests preliminary data being presented at the 21st Annual International Symposium on Endovascular Therapy (ISET).

Stents have long been used to open up blocked blood vessels in the heart to prevent heart attacks and in the neck to prevent strokes. More recently stents have been used in the heart to treat occurring heart attacks by opening up the blocked arteries. This early research suggests stents also can be used to treat occurring strokes, by opening up blocked arteries in the brain.

Treatments for ischemic stroke currently include delivering clot-busting drugs to the blockage through the veins or directly into the clot through an artery, or by removing the clot with a tiny corkscrew-like device or vacuuming it out. But early research suggests stents may work better than those treatments.

"Most patients had significant improvement; for instance, they could go home rather than having to be placed in a nursing home, which is pretty dramatic," said L. Nelson Hopkins, M.D., professor and chairman of neurosurgery and professor of radiology at the State University of New York at Buffalo, who is presenting the data at ISET. "Stents seem to work when clot-busters or other mechanical devices can't."

The third-leading cause of death in the U.S., stroke is called a brain attack because blood flow and oxygen to part of the brain is cut off. About 85 percent of strokes are ischemic, meaning they're caused by a blocked blood vessel. About 700,000 people suffer an ischemic stroke every year. The remaining 15 percent of strokes are hemorrhagic and are caused by a broken blood vessel. The lack of blood flow and oxygen to the site of the stroke causes the brain tissue to die. About a quarter of people who suffer a stroke die. Another third are severely disabled and may be paral
'/>"/>

SOURCE International Symposium on Endovascular Therapy
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
2. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
3. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
4. Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents
5. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
6. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
7. Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents
8. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
9. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
10. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
11. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3JAG Media Holdings Inc Amends Articles of Incorporation 58781 1JAG Media Holdings Inc Amends Articles of Incorporation 58781 2Vermillion Announces Return of Eric Fung M D Ph D 14338 1Vermillion Announces Return of Eric Fung M D Ph D 14338 2Vermillion Announces Return of Eric Fung M D Ph D 14338 3Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 1Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 2